UK NAO calls for curb on Rx drug wastage

21 January 2008

"Unused and wasted drugs" cost the UK's National Health Service at least L100.0 million ($195.9 million) a year, according to Edward Leigh, a Member of Parliament and Chairman of the Committee of Public Accounts, discussing the findings of a new report from the National Audit Office. This also found that the pharmaceutical industry spends some L850.0 million a year on marketing its products to general practitioners.

Among the suggestions in the NAO report, which was released as this issue of the Marketletter was going to press and will be fully reported next week, it proposed, among other moves, that the price of drugs be published on the packaging, in order to make patients more aware of their costs to avoid wastage, and that GPs be encouraged to prescribe more generic copy drugs instead of the more expensive branded products. This, it said, could save L200.0 million a year, without compromising clinical outcomes, noting that prescription medicines cost the NHS L8.2 billion in 2006, over double that of 1996.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK







Today's issue

Company Spotlight